TG-02 is a potent tyrosine kinase inhibitor primarily developed as an epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer and other EGFR-driven malignancies.… Read more
TG-02 is a potent tyrosine kinase inhibitor primarily developed as an epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer and other EGFR-driven malignancies. This category contains high-quality reference standards, including the active pharmaceutical ingredient, Zotiraciclib, and its stable isotope labelled analogues, such as TG-02-d3 and TG-02-13C-d3. Laboratories utilize these compounds as internal standards to ensure precise and accurate quantification during bioanalytical method validation, pharmacokinetic studies, and complex impurity profiling. By providing reliable materials for quantitative mass spectrometry, these stable isotope labelled compounds support rigorous quality control processes throughout pharmaceutical development and research. The availability of these distinct standards allows analytical chemists to overcome challenges in matrix interference, ensuring robust data in the study and monitoring of this specific kinase inhibitor and its related metabolic pathways.